JP2022530438A5 - - Google Patents

Info

Publication number
JP2022530438A5
JP2022530438A5 JP2021563155A JP2021563155A JP2022530438A5 JP 2022530438 A5 JP2022530438 A5 JP 2022530438A5 JP 2021563155 A JP2021563155 A JP 2021563155A JP 2021563155 A JP2021563155 A JP 2021563155A JP 2022530438 A5 JP2022530438 A5 JP 2022530438A5
Authority
JP
Japan
Application number
JP2021563155A
Other languages
Japanese (ja)
Other versions
JP2022530438A (ja
JPWO2020219775A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029657 external-priority patent/WO2020219775A1/en
Publication of JP2022530438A publication Critical patent/JP2022530438A/ja
Publication of JPWO2020219775A5 publication Critical patent/JPWO2020219775A5/ja
Publication of JP2022530438A5 publication Critical patent/JP2022530438A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563155A 2019-04-24 2020-04-23 抗cd117抗体薬物複合体およびその使用 Withdrawn JP2022530438A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838293P 2019-04-24 2019-04-24
US62/838,293 2019-04-24
PCT/US2020/029657 WO2020219775A1 (en) 2019-04-24 2020-04-23 Anti-cd117 antibody-drug conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2022530438A JP2022530438A (ja) 2022-06-29
JPWO2020219775A5 JPWO2020219775A5 (https=) 2023-05-01
JP2022530438A5 true JP2022530438A5 (https=) 2023-05-01

Family

ID=72940987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563155A Withdrawn JP2022530438A (ja) 2019-04-24 2020-04-23 抗cd117抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220175944A1 (https=)
EP (1) EP3958909A4 (https=)
JP (1) JP2022530438A (https=)
WO (1) WO2020219775A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
CN113993550A (zh) * 2019-04-24 2022-01-28 美真达治疗公司 用于基因疗法的调理方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
WO2022132929A2 (en) * 2020-12-16 2022-06-23 Vera Therapeutics, Inc. Multispecific antibody molecules and uses thereof
WO2022187050A1 (en) * 2021-03-01 2022-09-09 BioLegend, Inc. Anti-cd117 agents and compositions and methods for making and using the same
CN117683079B (zh) * 2023-12-12 2025-04-04 九洲药业(杭州)有限公司 一种抗体偶联药物连接子的固相合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006532A1 (en) * 2001-03-20 2004-01-08 David Lawrence Network access risk management
ES2882360T3 (es) * 2006-11-03 2021-12-01 Univ Leland Stanford Junior Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
CN116574185A (zh) * 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2015112822A1 (en) * 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
US11643668B2 (en) * 2015-06-17 2023-05-09 The Uab Research Foundation CRISPR/Cas9 complex for genomic editing
EP3370768B9 (en) * 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
JP2022512781A (ja) * 2018-10-30 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド 同種造血幹細胞移植の方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022530438A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2022530442A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)